Literature DB >> 33997937

Single nucleotide polymorphisms of TRAF2 and TRAF5 gene in ankylosing spondylitis: a case-control study.

Shanshan Xu1,2, Jiangping Kong1,2, Li Huang3, Huimin Xie1,2, Feier Wang1,2, Tingting Zhou1,2, Xiaoyi Zhang4, Lingxiang Yu1,2, Shengqian Xu5, Faming Pan6,7.   

Abstract

Objective To investigate the role of eight locus polymorphisms of tumor necrosis factor receptor-associated factor 2 (TRAF2) and TRAF5 gene and their interaction in the susceptibility to ankylosing spondylitis (AS) in Chinese Han population. Methods Eight single nucleotide polymorphisms (SNPs) of TRAF2 (rs3750511, rs10781522, rs17250673, rs59471504) and TRAF5 (rs6540679, rs12569232, rs4951523, rs7514863) gene were genotyped in 673 AS patients and 687 controls. Results The SNPs of TRAF2 and TRAF5 do not indicate a correlation with the susceptibility of AS in Chinese Han population. Genotype frequencies of rs3750511 were statistically significant in females between patients and controls. The allele frequencies of rs10781522 and genotype frequencies of rs3750511 were statistically significant between groups of different diseases activity. One three-locus model, TRAF2 (rs10781522, rs17250673) and TRAF5 (rs12569232), had a maximum testing accuracy of 52.67% and a maximum cross-validation consistency (10/10) that was significant at the level of P = 0.0001, after determined empirically by permutation testing. As to environmental variables, only marginal association was found between sleep quality and AS susceptibility. Conclusion TRAF2 rs3750511 polymorphism may be associated with the susceptibility and severity of AS. Besides, the interaction of TRAF2 and TRAF5 genes may be associated with AS susceptibility, but many open questions remain.
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Entities:  

Keywords:  Ankylosing spondylitis; Gene–gene interaction; Single nucleotide polymorphisms; TRAF2; TRAF5

Mesh:

Substances:

Year:  2021        PMID: 33997937     DOI: 10.1007/s10238-021-00719-7

Source DB:  PubMed          Journal:  Clin Exp Med        ISSN: 1591-8890            Impact factor:   3.984


  39 in total

Review 1.  The pathogenetic role of HLA-B27 and its subtypes.

Authors:  Muhammad Asim Khan; Alessandro Mathieu; Rosa Sorrentino; Nurullah Akkoc
Journal:  Autoimmun Rev       Date:  2006-12-08       Impact factor: 9.754

Review 2.  HLA-B27 and its subtypes in world populations.

Authors:  M A Khan
Journal:  Curr Opin Rheumatol       Date:  1995-07       Impact factor: 5.006

Review 3.  A review of work-participation, cost-of-illness and cost-effectiveness studies in ankylosing spondylitis.

Authors:  Annelies Boonen
Journal:  Nat Clin Pract Rheumatol       Date:  2006-10

4.  Ankylosing spondylitis and HL-A 27.

Authors:  D A Brewerton; F D Hart; A Nicholls; M Caffrey; D C James; R D Sturrock
Journal:  Lancet       Date:  1973-04-28       Impact factor: 79.321

5.  Effects of global postural reeducation exercise and anti-TNF treatments on disease activity, function, fatigue, mobility, sleep quality and depression in patients with active Ankylosing spondylitis: A prospective follow-up study.

Authors:  Neslihan Hezer Coksevim; Dilek Durmus; Omer Kuru
Journal:  J Back Musculoskelet Rehabil       Date:  2018       Impact factor: 1.398

Review 6.  Epidemiology of spondyloarthritis in the People's Republic of China: review of the literature and commentary.

Authors:  Swee Cheng Ng; Zetao Liao; David Tak Tan Yu; Edwin Shih Yen Chan; Like Zhao; Jieruo Gu
Journal:  Semin Arthritis Rheum       Date:  2007-03-13       Impact factor: 5.532

Review 7.  Surgical Treatment for Odontoid Fractures in Patients with Long-Standing Ankylosing Spondylitis: A Report of 3 Cases and Review of the Literature.

Authors:  Jinhao Miao; Yu Chen; Bangke Zhang; Tiefeng Li; Yibing Luo; Lei Shi; Jiangang Shi; Deyu Chen
Journal:  World Neurosurg       Date:  2018-05-17       Impact factor: 2.104

8.  A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab - a new side effect after 15 years of usage.

Authors:  Tomislava Skuhala; Anita Atelj; Jelena Prepolec; Mahmoud Al-Mufleh; Andrija Stanimirović; Dalibor Vukelić
Journal:  BMC Infect Dis       Date:  2019-02-07       Impact factor: 3.090

9.  Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.

Authors:  Dominique Baeten; Xenofon Baraliakos; Jürgen Braun; Joachim Sieper; Paul Emery; Désirée van der Heijde; Iain McInnes; Jacob M van Laar; Robert Landewé; Paul Wordsworth; Jürgen Wollenhaupt; Herbert Kellner; Jacqueline Paramarta; Jiawei Wei; Arndt Brachat; Stephan Bek; Didier Laurent; Yali Li; Ying A Wang; Arthur P Bertolino; Sandro Gsteiger; Andrew M Wright; Wolfgang Hueber
Journal:  Lancet       Date:  2013-09-13       Impact factor: 79.321

Review 10.  Immunogenetic study in Chinese population with ankylosing spondylitis: are there specific genes recently disclosed?

Authors:  Jiayu Zhai; Ju Rong; Qiuxia Li; Jieruo Gu
Journal:  Clin Dev Immunol       Date:  2013-01-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.